Sherley Wang

Dr. Sherley Wang has over 16 years of experience in the pharmaceutical industry, including 11 years in pharmacovigilance and 5 years in clinical quality assurance. She has worked with leading multinational pharmaceutical companies and completed over 200 audits of hospital research centers and 150 audits of CROs and pharma companies. She is also an authorised RPPV/QPPV for several domestic pharma companies.

She authored the China Pharmacovigilance Industry Research Report 2024 and contributed to the translation of key pharmacovigilance books in collaboration with the CDE of NMPA. Sherley is a panel expert at the China Food and Drug Industries Quality and Safety Promotion Association (FDSA). She also teaches pharmacovigilance to graduate students at Tongji Medical College, Huazhong University of Science and Technology. She published a research report titled “2024 China Pharmacovigilance Industry Research Report”, which received widespread attention in the industry.

As a member of the China Institute of Internal Audit (CIIA), Sherley is well-versed in GCP, GLP, GVP, and supplier audits, as well as regulatory inspections. She has deep knowledge of both domestic and international regulatory environments. Her experience enables her to support the setup and oversight of compliant PV systems for pharma companies.